Welcome to our dedicated page for Thermo Fisher Scientific news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fisher Scientific stock.
Thermo Fisher Scientific, Inc. (TMO) is a global leader in providing science-based solutions, offering a wide range of products and services in the life sciences, analytical instruments, specialty diagnostics, and laboratory products sectors. The company's expansive portfolio includes scientific instruments, laboratory equipment, diagnostic consumables, and life science reagents, serving customers both in the United States and internationally.
Thermo Fisher operates through four distinct segments as of end-2023:
- Analytical Technologies (17% of sales): This segment focuses on providing high-quality instruments and software solutions for various scientific applications.
- Specialty Diagnostic Products (10% of sales): This segment specializes in offering diagnostic reagents and instruments for medical and research laboratories.
- Life Science Solutions (23% of sales): This segment provides reagents, instruments, and consumables used in biological research and drug development.
- Lab Products and Services (54% of sales): This is the largest segment, encompassing laboratory supplies, equipment, and contract research organization (CRO) services.
Thermo Fisher is continually expanding its offerings and capabilities through strategic partnerships, acquisitions, and technological innovation. The company's robust financial performance underscores its leadership in the industry, driven by consistent revenue growth, strong market presence, and a commitment to advancing scientific research and healthcare.
Recent achievements include technological advancements in analytical instruments, enhanced diagnostic solutions, and expanded biopharma services, reflecting Thermo Fisher's dedication to supporting life-saving research and diagnostic processes. Thermo Fisher remains committed to delivering high-quality products and services, fostering scientific breakthroughs, and maintaining its position at the forefront of scientific innovation.
NATICK, Mass. - Mercy BioAnalytics announced that Dawn Mattoon, PhD, has taken over as Chief Executive Officer, transitioning from her previous role as Chief Operating Officer. Paul Blavin has moved to the position of Vice Chairman of the Board. Dr. Mattoon, who has been with the company for seven months, praised the team's progress in advancing their cancer detection technology. Her experience includes leadership roles in strategic initiatives at companies like Quanterix and Thermo Fisher Scientific. The company focuses on the early detection of cancers, particularly ovarian and lung cancers, through its Mercy Halo liquid biopsy platform.
Thermo Fisher Scientific (NYSE: TMO) announced a major step towards achieving its net-zero carbon emissions goal by 2050. The company signed a 20-year virtual power purchasing agreement with EDF Renewables to supply 545,000 MWh of renewable electricity annually from a new 200 MW solar project in Texas. By 2026, Thermo Fisher aims to power all U.S. operations entirely with renewable electricity. This initiative supports an increased target to cut Scope 1 and 2 greenhouse gas emissions by 50% from 2018 levels by 2030. The Millers Branch Solar project is set to be operational by December 2025, marking a significant shift toward sustainable practices.
Thermo Fisher Scientific Inc. (TMO) reported its Q4 and full-year 2022 results, showing a 7% increase in quarterly revenue to $11.45 billion and a 15% increase in annual revenue to $44.92 billion. The fourth quarter GAAP EPS was $4.01, down from $4.17 in 2021, while adjusted EPS was $5.40, compared to $6.54 previously. Notable achievements included the launch of innovative products and expansions in global capabilities. The company initiated 2023 guidance, expecting $45.3 billion in revenue and $23.70 in adjusted EPS.
Thermo Fisher Scientific Inc. (NYSE: TMO) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 10:30 a.m. (EST). CEO Marc N. Casper will lead the presentation, showcasing the company's commitment to advancing science globally. Thermo Fisher, with an annual revenue of approximately $40 billion, aims to make the world healthier, cleaner, and safer.
Investors can access the presentation via the Investors section of their website.
Thermo Fisher Scientific Inc. (NYSE: TMO) is set to release its financial results for Q4 and full year 2022 on
Thermo Fisher Scientific has completed its acquisition of The Binding Site Group for £2.3 billion ($2.8 billion). This acquisition expands Thermo Fisher's Specialty Diagnostics segment, enhancing its capabilities in oncology testing for multiple myeloma. The Binding Site's offerings are crucial for early diagnosis and monitoring of blood cancers, significantly improving patient outcomes. The transaction is expected to boost adjusted earnings per share by $0.07 in 2023. Thermo Fisher continues to lead in serving science with a projected annual revenue of around $40 billion.
Thermo Fisher Scientific has announced the pricing of a €1.25 billion offering of euro-denominated senior notes. The offering includes €500 million of 3.200% senior notes due 2026 and €750 million of 3.650% senior notes due 2034. The expected closing date is on or about November 21, 2022. Proceeds from this offering will fund general corporate purposes, including acquisitions and debt refinancing. The company operates under an effective registration statement with the SEC, ensuring compliance and transparency for investors.
Thermo Fisher Scientific, trading under TMO, has announced the pricing of a $1.2 billion bond offering, which includes $600 million in senior notes due 2027 with a 4.800% interest rate and $600 million in senior notes due 2032 with a 4.950% interest rate. The offering is set to close by November 21, 2022, subject to standard conditions. Proceeds will support various corporate purposes, including debt repayment and acquisitions. The offering is managed by BofA Securities, Citigroup, and Deutsche Bank.
Thermo Fisher Scientific (NYSE: TMO) has authorized a substantial share repurchase program, amounting to $4 billion. This initiative allows for the repurchase of shares in the open market or through negotiated transactions, with no expiration date set for the authorization. This strategic move aims to enhance shareholder value and reflects the company's confidence in its strong financial position, supported by an annual revenue of approximately $40 billion.
FAQ
What is the current stock price of Thermo Fisher Scientific (TMO)?
What is the market cap of Thermo Fisher Scientific (TMO)?
What does Thermo Fisher Scientific, Inc. specialize in?
What are the main segments of Thermo Fisher Scientific?
How much of Thermo Fisher's sales come from Lab Products and Services?
Where does Thermo Fisher Scientific operate?
What recent achievements has Thermo Fisher Scientific made?
What is Thermo Fisher Scientific's stock symbol?
How does Thermo Fisher Scientific support scientific research?
What types of products does Thermo Fisher Scientific offer?
What is Thermo Fisher's commitment to the healthcare industry?
What sets Thermo Fisher Scientific apart in its industry?
